BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33899650)

  • 1. Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Zhan M; Chen ZB; Ding CC; Qu Q; Wang GQ; Liu S; Wen FQ
    Leuk Lymphoma; 2021 Oct; 62(10):2502-2513. PubMed ID: 33899650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
    Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
    Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis.
    Jian C; Chen S; Wang Z; Zhou Y; Zhang Y; Li Z; Jian J; Wang T; Xiang T; Wang X; Jia Y; Wang H; Gong J
    BMC Med Inform Decis Mak; 2023 Aug; 23(1):148. PubMed ID: 37537590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
    Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
    PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of significant risks in pediatric acute lymphoblastic leukemia (ALL) through machine learning (ML) approach.
    Mahmood N; Shahid S; Bakhshi T; Riaz S; Ghufran H; Yaqoob M
    Med Biol Eng Comput; 2020 Nov; 58(11):2631-2640. PubMed ID: 32840766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning.
    Zhan M; Chen Z; Ding C; Qu Q; Wang G; Liu S; Wen F
    Int J Hematol; 2021 Oct; 114(4):483-493. PubMed ID: 34170480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
    Tatsumoto C; Kawakami K; Nagayama J; Kawano H
    Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors.
    Wiley JM; Smith N; Leventhal BG; Graham ML; Strauss LC; Hurwitz CA; Modlin J; Mellits D; Baumgardner R; Corden BJ
    J Clin Oncol; 1990 Feb; 8(2):280-6. PubMed ID: 2299371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
    Kloos RQH; Pieters R; van den Bos C; van Eijkelenburg NKA; de Jonge R; van der Sluis IM
    Leuk Lymphoma; 2019 Dec; 60(12):3002-3010. PubMed ID: 31120351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
    J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.
    El-Khodary NM; El-Haggar SM; Eid MA; Ebeid EN
    Med Oncol; 2012 Sep; 29(3):2053-62. PubMed ID: 21644011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital].
    Moisă SM; Rusu A; Dumitraş S; Burlea M; Miron I
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(2):356-65. PubMed ID: 19295004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.